Lifecare ASA - Chief Scientific Officer to step down from executive role

13 Mar 2026 20:03 CET

Bergen, Norway, 13 March 2026 -- Lifecare ASA (LIFE), a MedTech company
developing next-generation implantable continuous glucose monitoring (CGM)
technology, announces that Prof. Dr. Dr. med. Andreas Pfützner has decided to
step down from his executive position as Chief Scientific Officer (CSO) of the
Company.

Prof. Pfützner has been a central contributor to the development of Lifecare's
technology platform and has worked closely with the Company for more than nine
years. The Company appreciates his significant contributions to the scientific
and technological development of Lifecare's implantable glucose monitoring
technology.

Lifecare is grateful that Prof. Pfützner has agreed to continue contributing
to the Company in an operational and supporting role. The Company will
evaluate how to best make use of his extensive scientific expertise, deep
knowledge of Lifecare's technology, and valuable insights into the diabetes
technology market going forward.

"Over the past nine years, Andreas has played a pivotal role in shaping
Lifecare's scientific foundation. His medical expertise, scientific leadership
and deep understanding of the diabetes technology field have been instrumental
in advancing our implantable CGM technology from concept to the stage we are
at today. On behalf of the Company and the Board, I would like to express my
sincere gratitude for his dedication and contributions to Lifecare," said
Joacim Holter, CEO of Lifecare ASA.

"As Lifecare now moves further into a phase increasingly focused on product
development, industrialization and preparation for market entry, the nature of
our operational priorities is evolving. We are therefore particularly pleased
that Andreas will continue to support the Company with his medical insight and
long-standing experience with our technology and the broader diabetes
technology landscape."

The Company will initiate a process to ensure continued leadership of its
scientific activities.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-03-13 20:03 CET.

More information:
Access the news on Oslo Bors NewsWeb site

668345_Lifecare ASA - Chief Scientific Officer to step down from executive role.pdf